Lee's Pharmaceutical Holdings Limited (FRA:L1PA)

FRA:L1PA Income Statement

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,436	1,400	1,053	1,233	1,266	1,217
Revenue Growth (YoY)	19.80%	32.95%	-14.61%	-2.61%	4.06%	-0.18%
Cost of Revenue	673.63	646.61	501.72	462.39	459.87	435.65
Gross Profit	762.81	753.36	551.31	770.76	806.28	781.07
Selling, General & Admin	567.45	582.59	492.91	544.88	663.7	517.67
Research & Development	91.36	83.83	96.8	168.89	243.84	203.29
Other Operating Expenses	-42.86	-60.32	-75.72	-70.19	-96.41	-90.46
Operating Expenses	629.93	619.8	515.27	643.31	901.41	631.68
Operating Income	132.88	133.55	36.04	127.44	-95.13	149.39
Interest Expense	-13.4	-13.82	-11.28	-6.62	-4.4	-5.39
Interest & Investment Income	2.19	2.13	1.53	2.39	5.91	9.07
Earnings From Equity Investments	-1.09	-0.84	-0.87	-1.1	-3.5	-11.41
Currency Exchange Gain (Loss)	3.61	3.61	-0.88	-5.63	3.05	0.21
Other Non Operating Income (Expenses)	-0.36	-0.37	-0.62	-0.98	-1.32	-1.09
EBT Excluding Unusual Items	123.84	124.27	23.93	115.51	-95.38	140.79
Impairment of Goodwill	-	-	-	-	-	-2.34
Gain (Loss) on Sale of Investments	-0.38	-0.38	-1.43	-46.36	2,300	-203.47
Gain (Loss) on Sale of Assets	0.14	0.14	41.63	0.24	0.04	155.66
Asset Writedown	-25.91	-25.91	-33.31	-2.68	-235.09	-4.14
Other Unusual Items	-	-	-0.04	1.15	-	47.55
Pretax Income	97.68	98.11	30.79	67.86	1,969	134.04
Income Tax Expense	33.39	29.5	10.84	22.03	9.48	55.5
Earnings From Continuing Operations	64.29	68.61	19.95	45.84	1,960	78.53
Minority Interest in Earnings	33.52	24.49	-3.25	5.45	27.29	50.78
Net Income	97.81	93.1	16.7	51.28	1,987	129.32
Net Income to Common	97.81	93.1	16.7	51.28	1,987	129.32
Net Income Growth	55.10%	457.55%	-67.44%	-97.42%	1436.68%	3.00%
Shares Outstanding (Basic)	589	589	589	589	589	588
Shares Outstanding (Diluted)	589	589	589	589	589	588
Shares Change (YoY)	-	-	-	-0.04%	0.15%	-0.63%
EPS (Basic)	0.17	0.16	0.03	0.09	3.38	0.22
EPS (Diluted)	0.17	0.16	0.03	0.09	3.37	0.22
EPS Growth	55.10%	457.53%	-67.44%	-97.42%	1434.25%	3.67%
Free Cash Flow	324.98	198.06	80.65	266.18	159.99	80.52
Free Cash Flow Per Share	0.55	0.34	0.14	0.45	0.27	0.14
Dividend Per Share	0.047	0.045	0.018	0.020	0.061	0.058
Dividend Growth	56.67%	150.00%	-10.00%	-67.21%	5.17%	3.57%
Gross Margin	53.10%	53.81%	52.35%	62.50%	63.68%	64.20%
Operating Margin	9.25%	9.54%	3.42%	10.33%	-7.51%	12.28%
Profit Margin	6.81%	6.65%	1.59%	4.16%	156.94%	10.63%
Free Cash Flow Margin	22.62%	14.15%	7.66%	21.58%	12.64%	6.62%
EBITDA	221.29	220.26	130.62	237.9	16.83	260.95
EBITDA Margin	15.40%	15.73%	12.40%	19.29%	1.33%	21.45%
D&A For EBITDA	88.41	86.71	94.58	110.46	111.96	111.56
EBIT	132.88	133.55	36.04	127.44	-95.13	149.39
EBIT Margin	9.25%	9.54%	3.42%	10.33%	-7.51%	12.28%
Effective Tax Rate	34.18%	30.07%	35.20%	32.46%	0.48%	41.41%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.